2017
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. British Journal Of Dermatology 2017, 177: 1562-1574. PMID: 28755394, DOI: 10.1111/bjd.15857.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBody surface areaABP 501Week 16Adverse eventsAntidrug antibodiesPlaque psoriasisBiosimilar ABP 501New safety signalsPercentage of patientsPhase III trialsSimilar clinical efficacySeverity Index scorePercentage body surface areaLong-term resultsEuropean Medicines AgencyPASI 50PASI improvementWeek 52III trialsPsoriasis AreaAdalimumab patientsImmunogenicity profileClinical efficacyPatient population
2012
Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link.
Marmon S, De Souza A, Strober B. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatology Online Journal 2012, 18: 13. PMID: 22747937, DOI: 10.5070/d305m5f4bx.Peer-Reviewed Original ResearchConceptsDown syndromeSerum levelsIFN-gammaChronic plaque psoriasisPotential pathophysiologic linksHigher serum levelsCases of patientsProduction of cytokinesTumor necrosis factorTh1 lineage cellsPathophysiologic linkPlaque psoriasisTh17 cellsTh17 pathwayPatient populationIL-2Healthy controlsNecrosis factorGreater prevalencePsoriasisSyndromeIFN systemPatientsLineage cellsCells